| . | Total . | Survivors . | Non-survivors . | P . |
|---|---|---|---|---|
| Number of patients | 62 | 44 | 18 | |
| Demographics | ||||
| Age, years, mean ± SD | 62.1±15.8 | 58.5±16.2 | 70.1±1v0.9 | 0.004 |
| Male, n (%) | 45 (72.6) | 32 (72.7) | 13 (72.2) | 0.968 |
| Principal diagnosis (%) | ||||
| Neurologic disease, n (%) | 4(6.45) | 2(4.55) | 2(11.11) | 0.573 |
| Digestive disease, n (%) | 9(14.52) | 5(11.36) | 4(22.22) | 0.427 |
| Poisoning, n (%) | 2(3.22) | 2(4.55) | 0 | 0.581 |
| Infectious disease and/or sepsis, n (%) | 26(41.94) | 17(36.36) | 9(50.00) | 0.257 |
| Trauma, n (%) | 18 (29.03) | 16 (36.36) | 2 (11.11) | 0.065 |
| Other, n (%) | 3 (4.84) | 2 (4.55) | 1 (5.56) | 0.866 |
| APACHE II score, median (IQ1-IQ3) | 22.5 (18.3–27.0) | 20.0 (16.8–26.3) | 26.0 (23.3–28.8) | 0.0103a |
| SOFA score, median (IQ1-IQ3) | 8 (5.3–11.8) | 8 (5.0–10.0) | 9.5 (8.0–12.0) | 0.0574 |
| IL-6, pg/ml, median (IQ1-IQ3) | 58.6 (28.0–153.0) | 48.8 (24.7–122.0) | 100.3 (53.0–180.5) | 0.9448 |
| PCT, ng/ml, median (IQ1-IQ3) | 0.97 (0.21–2.63) | 0.83 (0.19–2.56) | 1.27 (0.52–7.03) | 0.3550 |
| Thyroid hormone parameters | ||||
| TSH, mIU/L, median (IQ1-IQ3) | 0.46 (0.23–1.42) | 0.61 (0.26–1.52) | 0.32 (0.15–0.74) | 0.4958 |
| T3, nmol/L, median (IQ1-IQ3) | 0.74 (0.66–0.94) | 0.78 (0.67–0.93) | 0.70 (0.64–0.97) | 0.4207 |
| T4, nmol/L, median (IQ1-IQ3) | 56.0 (45.8–71.7) | 55.3 (47.1–73.2) | 60.7 (41.5–70.1) | 0.7234 |
| fT3, pmol/L, median (IQ1-IQ3) | 2.21 (1.81–2.74) | 2.37 (1.92–2.77) | 2.15 (1.65–2.61) | 0.3736 |
| fT4, pmol/L, median (IQ1-IQ3) | 12.7 (11.0–14.9) | 12.5 (10.9–13.9) | 13.5 (12.0–16.3) | 0.0636 |
| rT3, ng/ml, median (IQ1-IQ3) | 0.38 (0.29–0.57) | 0.35 (0.28–0.44) | 0.55 (0.39–0.60) | 0.0003* |
| . | Total . | Survivors . | Non-survivors . | P . |
|---|---|---|---|---|
| Number of patients | 62 | 44 | 18 | |
| Demographics | ||||
| Age, years, mean ± SD | 62.1±15.8 | 58.5±16.2 | 70.1±1v0.9 | 0.004 |
| Male, n (%) | 45 (72.6) | 32 (72.7) | 13 (72.2) | 0.968 |
| Principal diagnosis (%) | ||||
| Neurologic disease, n (%) | 4(6.45) | 2(4.55) | 2(11.11) | 0.573 |
| Digestive disease, n (%) | 9(14.52) | 5(11.36) | 4(22.22) | 0.427 |
| Poisoning, n (%) | 2(3.22) | 2(4.55) | 0 | 0.581 |
| Infectious disease and/or sepsis, n (%) | 26(41.94) | 17(36.36) | 9(50.00) | 0.257 |
| Trauma, n (%) | 18 (29.03) | 16 (36.36) | 2 (11.11) | 0.065 |
| Other, n (%) | 3 (4.84) | 2 (4.55) | 1 (5.56) | 0.866 |
| APACHE II score, median (IQ1-IQ3) | 22.5 (18.3–27.0) | 20.0 (16.8–26.3) | 26.0 (23.3–28.8) | 0.0103a |
| SOFA score, median (IQ1-IQ3) | 8 (5.3–11.8) | 8 (5.0–10.0) | 9.5 (8.0–12.0) | 0.0574 |
| IL-6, pg/ml, median (IQ1-IQ3) | 58.6 (28.0–153.0) | 48.8 (24.7–122.0) | 100.3 (53.0–180.5) | 0.9448 |
| PCT, ng/ml, median (IQ1-IQ3) | 0.97 (0.21–2.63) | 0.83 (0.19–2.56) | 1.27 (0.52–7.03) | 0.3550 |
| Thyroid hormone parameters | ||||
| TSH, mIU/L, median (IQ1-IQ3) | 0.46 (0.23–1.42) | 0.61 (0.26–1.52) | 0.32 (0.15–0.74) | 0.4958 |
| T3, nmol/L, median (IQ1-IQ3) | 0.74 (0.66–0.94) | 0.78 (0.67–0.93) | 0.70 (0.64–0.97) | 0.4207 |
| T4, nmol/L, median (IQ1-IQ3) | 56.0 (45.8–71.7) | 55.3 (47.1–73.2) | 60.7 (41.5–70.1) | 0.7234 |
| fT3, pmol/L, median (IQ1-IQ3) | 2.21 (1.81–2.74) | 2.37 (1.92–2.77) | 2.15 (1.65–2.61) | 0.3736 |
| fT4, pmol/L, median (IQ1-IQ3) | 12.7 (11.0–14.9) | 12.5 (10.9–13.9) | 13.5 (12.0–16.3) | 0.0636 |
| rT3, ng/ml, median (IQ1-IQ3) | 0.38 (0.29–0.57) | 0.35 (0.28–0.44) | 0.55 (0.39–0.60) | 0.0003* |
P < 0.05, Quantitative data are represented as mean ± SD. Comparisons were done using Fisher’s exact test for categorical variables and Mann–Whitney U test for continuous variables. SOFA sequential organ failure assessment, APPACHE II Acute Physiology and Chronic Health Evaluation, IL-6 interleukin 6, PCT procalcitonin, TSH thyroid stimulating hormone, T3 triiodothyronine, T4 thyroxine, rT3 reverse, T3, ICU Intensive Care Unit
| . | Total . | Survivors . | Non-survivors . | P . |
|---|---|---|---|---|
| Number of patients | 62 | 44 | 18 | |
| Demographics | ||||
| Age, years, mean ± SD | 62.1±15.8 | 58.5±16.2 | 70.1±1v0.9 | 0.004 |
| Male, n (%) | 45 (72.6) | 32 (72.7) | 13 (72.2) | 0.968 |
| Principal diagnosis (%) | ||||
| Neurologic disease, n (%) | 4(6.45) | 2(4.55) | 2(11.11) | 0.573 |
| Digestive disease, n (%) | 9(14.52) | 5(11.36) | 4(22.22) | 0.427 |
| Poisoning, n (%) | 2(3.22) | 2(4.55) | 0 | 0.581 |
| Infectious disease and/or sepsis, n (%) | 26(41.94) | 17(36.36) | 9(50.00) | 0.257 |
| Trauma, n (%) | 18 (29.03) | 16 (36.36) | 2 (11.11) | 0.065 |
| Other, n (%) | 3 (4.84) | 2 (4.55) | 1 (5.56) | 0.866 |
| APACHE II score, median (IQ1-IQ3) | 22.5 (18.3–27.0) | 20.0 (16.8–26.3) | 26.0 (23.3–28.8) | 0.0103a |
| SOFA score, median (IQ1-IQ3) | 8 (5.3–11.8) | 8 (5.0–10.0) | 9.5 (8.0–12.0) | 0.0574 |
| IL-6, pg/ml, median (IQ1-IQ3) | 58.6 (28.0–153.0) | 48.8 (24.7–122.0) | 100.3 (53.0–180.5) | 0.9448 |
| PCT, ng/ml, median (IQ1-IQ3) | 0.97 (0.21–2.63) | 0.83 (0.19–2.56) | 1.27 (0.52–7.03) | 0.3550 |
| Thyroid hormone parameters | ||||
| TSH, mIU/L, median (IQ1-IQ3) | 0.46 (0.23–1.42) | 0.61 (0.26–1.52) | 0.32 (0.15–0.74) | 0.4958 |
| T3, nmol/L, median (IQ1-IQ3) | 0.74 (0.66–0.94) | 0.78 (0.67–0.93) | 0.70 (0.64–0.97) | 0.4207 |
| T4, nmol/L, median (IQ1-IQ3) | 56.0 (45.8–71.7) | 55.3 (47.1–73.2) | 60.7 (41.5–70.1) | 0.7234 |
| fT3, pmol/L, median (IQ1-IQ3) | 2.21 (1.81–2.74) | 2.37 (1.92–2.77) | 2.15 (1.65–2.61) | 0.3736 |
| fT4, pmol/L, median (IQ1-IQ3) | 12.7 (11.0–14.9) | 12.5 (10.9–13.9) | 13.5 (12.0–16.3) | 0.0636 |
| rT3, ng/ml, median (IQ1-IQ3) | 0.38 (0.29–0.57) | 0.35 (0.28–0.44) | 0.55 (0.39–0.60) | 0.0003* |
| . | Total . | Survivors . | Non-survivors . | P . |
|---|---|---|---|---|
| Number of patients | 62 | 44 | 18 | |
| Demographics | ||||
| Age, years, mean ± SD | 62.1±15.8 | 58.5±16.2 | 70.1±1v0.9 | 0.004 |
| Male, n (%) | 45 (72.6) | 32 (72.7) | 13 (72.2) | 0.968 |
| Principal diagnosis (%) | ||||
| Neurologic disease, n (%) | 4(6.45) | 2(4.55) | 2(11.11) | 0.573 |
| Digestive disease, n (%) | 9(14.52) | 5(11.36) | 4(22.22) | 0.427 |
| Poisoning, n (%) | 2(3.22) | 2(4.55) | 0 | 0.581 |
| Infectious disease and/or sepsis, n (%) | 26(41.94) | 17(36.36) | 9(50.00) | 0.257 |
| Trauma, n (%) | 18 (29.03) | 16 (36.36) | 2 (11.11) | 0.065 |
| Other, n (%) | 3 (4.84) | 2 (4.55) | 1 (5.56) | 0.866 |
| APACHE II score, median (IQ1-IQ3) | 22.5 (18.3–27.0) | 20.0 (16.8–26.3) | 26.0 (23.3–28.8) | 0.0103a |
| SOFA score, median (IQ1-IQ3) | 8 (5.3–11.8) | 8 (5.0–10.0) | 9.5 (8.0–12.0) | 0.0574 |
| IL-6, pg/ml, median (IQ1-IQ3) | 58.6 (28.0–153.0) | 48.8 (24.7–122.0) | 100.3 (53.0–180.5) | 0.9448 |
| PCT, ng/ml, median (IQ1-IQ3) | 0.97 (0.21–2.63) | 0.83 (0.19–2.56) | 1.27 (0.52–7.03) | 0.3550 |
| Thyroid hormone parameters | ||||
| TSH, mIU/L, median (IQ1-IQ3) | 0.46 (0.23–1.42) | 0.61 (0.26–1.52) | 0.32 (0.15–0.74) | 0.4958 |
| T3, nmol/L, median (IQ1-IQ3) | 0.74 (0.66–0.94) | 0.78 (0.67–0.93) | 0.70 (0.64–0.97) | 0.4207 |
| T4, nmol/L, median (IQ1-IQ3) | 56.0 (45.8–71.7) | 55.3 (47.1–73.2) | 60.7 (41.5–70.1) | 0.7234 |
| fT3, pmol/L, median (IQ1-IQ3) | 2.21 (1.81–2.74) | 2.37 (1.92–2.77) | 2.15 (1.65–2.61) | 0.3736 |
| fT4, pmol/L, median (IQ1-IQ3) | 12.7 (11.0–14.9) | 12.5 (10.9–13.9) | 13.5 (12.0–16.3) | 0.0636 |
| rT3, ng/ml, median (IQ1-IQ3) | 0.38 (0.29–0.57) | 0.35 (0.28–0.44) | 0.55 (0.39–0.60) | 0.0003* |
P < 0.05, Quantitative data are represented as mean ± SD. Comparisons were done using Fisher’s exact test for categorical variables and Mann–Whitney U test for continuous variables. SOFA sequential organ failure assessment, APPACHE II Acute Physiology and Chronic Health Evaluation, IL-6 interleukin 6, PCT procalcitonin, TSH thyroid stimulating hormone, T3 triiodothyronine, T4 thyroxine, rT3 reverse, T3, ICU Intensive Care Unit
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
